MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.510
-0.060
-3.82%
After Hours: 1.510 0 0.00% 16:07 01/17 EST
OPEN
1.550
PREV CLOSE
1.570
HIGH
1.570
LOW
1.500
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
2.340
52 WEEK LOW
1.020
MARKET CAP
311.68M
P/E (TTM)
-5.8641
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MNKD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MNKD News

  • Top Picks 2020- MannKind MNKD
  • MoneyShow.01/10 10:00
  • Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month
  • GlobeNewswire.01/06 13:00
  • MannKind: MidCap Amendment And Warrants
  • Seeking Alpha - Article.12/27/2019 17:55
  • Benzinga's Top Upgrades, Downgrades For December 24, 2019
  • Benzinga.12/24/2019 15:49

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About MNKD

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
More

Webull offers MannKind Corporation (MNKD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.